Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 38.7849
- Book/Share 32.6431
- PB 7.1409
- Debt/Equity 0.5777
- CurrentRatio 1.0736
- ROIC 0.142
- MktCap 561606688276.0
- FreeCF/Share 7.8498
- PFCF 29.459
- PE 21.1202
- Debt/Assets 0.2375
- DivYield 0.0221
- ROE 0.3488
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Morgan Stanley | Equal Weight | Overweight | -- | $262 | Jan. 28, 2026 |
| Initiation | JNJ | Scotiabank | -- | Sector Outperform | -- | $230 | Nov. 13, 2025 |
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
What's Behind The 50% Surge In JNJ Stock?
Published: February 03, 2026 by: Forbes
Sentiment: Positive
In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)'s stock experienced a remarkable 52% increase, driven by improved earnings, significant product achievements, and advancements in legal matters. Behind this 3.2% uplift in revenue and enhancement in margins is a narrative of innovation, effective risk management, and strategic evolution—let's delve into what has influenced this change.
Read More
Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
World's #1 Selling Contact Lens Brand ACUVUE®*1 Brings Pioneering Innovation For Astigmatic Patients With Presbyopia, Providing Visual Clarity And Comfort**2
Read More
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
Published: January 30, 2026 by: Seeking Alpha
Sentiment: Negative
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
Read More
This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks
Published: January 29, 2026 by: Barrons
Sentiment: Positive
Susan Bao's large-cap JPMorgan fund has outperformed the S&P 500 over many years. She's bullish on stocks, focused on bargains.
Read More
Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B, with Innovative Medicine and MedTech growth offsetting Stelara LOE.
Read More
Johnson & Johnson: Strong Momentum Heading Into 2026
Published: January 28, 2026 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience. Their deal with the Trump Administration eliminates tariffs in exchange for lower drug prices. This is expected to provide gross margin relief despite some remaining pressure. Guidance for 2026 calls for accelerating top-line growth and at least 50bps pre-tax operating margin expansion. They also have longer-term double-digit growth ambitions.
Read More
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
Published: January 27, 2026 by: PRNewsWire
Sentiment: Neutral
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth indication for DARZALEX FASPRO ® and fifth in the newly diagnosed setting, underscoring its role as foundational therapy for both newly diagnosed and relapsed/refractory multiple myeloma patients HORSHAM, Pa., Jan. 27, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who …
Read More
J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
On its fourth-quarter earnings conference call on Jan. 21, Johnson & Johnson JNJ announced its financial outlook for 2026, which exceeded consensus expectations.
Read More
The 3 Dividend Stocks I Think Every Investor Should Own Right Now
Published: January 26, 2026 by: 24/7 Wall Street
Sentiment: Positive
The current macro investing climate is one in which investors have plenty to consider.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ beat Q4 earnings and sales estimates and sees 2026 free cash flow rising to $21B, making healthcare ETFs a safer way to play its momentum.
Read More
Johnson & Johnson Quietly Triggers a Trend Following Buy Signal
Published: January 23, 2026 by: MarketBeat
Sentiment: Neutral
Johnson & Johnson NYSE: JNJ, amid the noise of Trump's Greenland agenda and renewed trade war fears, is quietly executing its healthcare strategy, growing revenue and widening margins, setting its stock up to continue trending higher. A recent earnings release and 2026 guidance update, though strong, triggered a price pullback and a trend-following opportunity.
Read More
Goldman Sachs Says Correction Could Be Coming: 5 Safe Dividend Stocks From the Conviction List
Published: January 23, 2026 by: 24/7 Wall Street
Sentiment: Positive
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest U.S.
Read More
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Read More
J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Neutral
JNJ beat Q4 earnings and sales estimates as strong oncology drug growth, led by Darzalex, offset biosimilar pressure on Stelara.
Read More
Johnson & Johnson reports Q4 earnings beat, issues 2026 guidance above forecasts
Published: January 21, 2026 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ) reported fourth quarter and full-year 2025 results that came in above market expectations and issued 2026 guidance that was modestly ahead forecasts. For Q4, Johnson & Johnson reported sales of $24.6 billion, representing reported growth of 9.1% year-over-year and operational growth of 7.1%.
Read More
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Negative
JNJ heads into Q4 earnings with strong pharma and MedTech momentum, offset by Stelara biosimilar pressure and China-related headwinds.
Read More
3 Dividend Stocks to Own No Matter Where the Market Moves in 2026
Published: January 19, 2026 by: 24/7 Wall Street
Sentiment: Positive
It is possible to build wealth through dividend investing. While it isn't guaranteed that your investment will grow, you'll continue to enjoy passive income as long as you hold the stock.
Read More
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Read More
Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings, Beyond Revenue and EPS
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
Read More
J&J's Innovative Medicine Segment in Q4: Here's What to Watch
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.
Read More
JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100